Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $30.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 373.19% from the stock's current price.
VYGR has been the subject of a number of other reports. Wedbush decreased their target price on Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, August 7th. StockNews.com downgraded Voyager Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday. Leerink Partnrs raised Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. Finally, Leerink Partners started coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $17.00.
Check Out Our Latest Analysis on VYGR
Voyager Therapeutics Stock Performance
Shares of NASDAQ:VYGR traded down $0.35 on Thursday, hitting $6.34. 490,294 shares of the company's stock were exchanged, compared to its average volume of 641,518. The company has a market capitalization of $345.74 million, a PE ratio of 9.00 and a beta of 0.89. Voyager Therapeutics has a 1-year low of $5.71 and a 1-year high of $11.72. The firm's 50-day moving average is $6.63 and its 200 day moving average is $7.53.
Insider Transactions at Voyager Therapeutics
In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares of the company's stock, valued at $500,525.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.53% of the company's stock.
Institutional Investors Weigh In On Voyager Therapeutics
A number of large investors have recently bought and sold shares of VYGR. Ameritas Investment Partners Inc. boosted its holdings in shares of Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock worth $37,000 after purchasing an additional 1,300 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in shares of Voyager Therapeutics during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter worth $74,000. Finally, SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics in the 2nd quarter worth $85,000. Institutional investors and hedge funds own 48.03% of the company's stock.
Voyager Therapeutics Company Profile
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
See Also
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
